Stocks and Investing
Stocks and Investing
Thu, September 9, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, September 8, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Maintained (SWTX) at Buy with Increased Target to $105 on, Sep 8th, 2021
Anupam Rama of JP Morgan, Maintained "SpringWorks Therapeutics, Inc." (SWTX) at Buy with Increased Target from $97 to $105 on, Sep 8th, 2021.
Anupam has made no other calls on SWTX in the last 4 months.
There is 1 other peer that has a rating on SWTX. Out of the 1 peers that are also analyzing SWTX, 0 agree with Anupam's Rating of Hold.
This is the rating of the analyst that currently disagrees with Anupam
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $137 on, Thursday, August 5th, 2021
Contributing Sources